Quinolinone HCV Inhibitors for Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis C virus (HCV) therapies face challenges such as limited efficacy, significant side effects, emergence of resistance, and compliance issues due to sub-optimal pharmacokinetics, necessitating the development of more effective, tolerable, and convenient treatments with improved antiviral efficacy and reduced toxicity.
Innovation Solution
Development of hetero-bicyclic derivatives, specifically quinolinone derivatives, which act as HCV inhibitors with favorable pharmacokinetics, reduced toxicity, and minimal drug interactions, designed to target the NS5A protein of HCV, offering a potential treatment for HCV infection with improved efficacy and safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HCV therapies (interferon-alpha and ribavirin combination) are used, then antiviral efficacy is achieved, but significant side effects and limited efficacy on HCV genotype 1 occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of HCV inhibitors through hetero-bicyclic derivatives with specific substituents (R1-R6 groups, heteroatoms X1-X6). These structural parameter changes aim to improve antiviral efficacy while reducing side effects by optimizing the balance between potency and tolerability, directly addressing the contradiction between efficacy and harmful effects of current therapies
Solution Approach 2:
The patent employs composite materials by creating hetero-bicyclic derivative compounds that combine multiple functional groups and heteroatoms (nitrogen, oxygen, sulfur) within a single molecular structure. This composite approach allows the drug to achieve both high antiviral activity and reduced toxicity by integrating multiple pharmacophores that work synergistically to improve the therapeutic index
2Ease of operation
If sub-optimal pharmacokinetics and complex dosing regimens are used, then treatment is administered, but compliance failures and inadequate trough levels occur
Solution Approach 1:
The patent applies parameter changes by optimizing pharmacokinetic parameters through molecular structure modification. The hetero-bicyclic derivatives are designed with specific physical-chemical properties (solubility, stability, metabolic resistance) that enable achievement of adequate 24-hour trough levels with simplified dosing, directly resolving the contradiction between dosing complexity and compliance reliability
3Reliability
If HCV inhibitors with broad activity are developed, then antiviral efficacy is improved, but drug-drug interactions and resistance development increase
Solution Approach 1:
The patent applies local quality by designing hetero-bicyclic derivatives with specific localized functional groups (R1-R6 substituents, heteroatom positions X1-X6) that target HCV with high specificity. This localized optimization allows the drug to maintain potent antiviral activity while minimizing off-target effects and resistance development by precisely tuning the interaction with HCV proteins rather than achieving broad-spectrum activity
Data Source
AI summary
Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R' have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors,in HCV therapy.